Introduction
The single-stranded DNA-binding proteins (SSBPs (SSBP2, 3 and 4)) interact with the transcriptional cofactor LIM domain-binding protein 1 (LDB1) through a highly conserved amino terminal motif (Chen et al., 2002; van Meyel et al., 2003) . LDB1 in turn binds to the LIM domain of LIM homeodomain (LHX) and LIM only (LMO) proteins with high affinity to assemble multi-protein complexes (Agulnick et al., 1996; Goardon et al., 2006) . The activity of LDB1-containing complexes is also regulated by the E3 ubiquitin ligase ring finger protein 12 (RNF12/RLIM), which promotes rapid turnover of LDB1 (Bach et al., 1999) . As LIM domains do not bind DNA but mediate protein-protein interactions, target genes are recognized by the homeodomain in LHX or by LMO interaction with E boxbinding basic helix-loop-helix transcription factors (Goardon et al., 2006) . Despite the genetic evidence for stringent regulation of these LIM domain-containing complexes, the contribution of individual SSBP members in regulating LDB1 levels in vivo is unknown.
Human SSBP2 was isolated as a candidate myeloid leukemia suppressor from a critical region of loss at 5q13-14 (Castro et al., 2002) . Independent of the gene discovery, global expression profiling revealed loss of SSBP2 expression in a subset of therapy-induced acute myeloid leukemia with 5q deletion (Qian et al., 2002) . Inducible expression of SSBP2 in the acute myeloid leukemia cell line U937 resulted in growth arrest and partial differentiation (Liang et al., 2005) . Furthermore, adenoviral oncoprotein E1B55K directly binds and sequesters SSBP2 to juxtanuclear aggresomes, suggesting a broader role for disruption of normal SSBP2 function during transformation (Fleisig et al., 2007) . Accumulating evidence suggests a tumor suppressor function for SSBP2: (i) Retroviral integration-mediated disruption leading to reduced expression of SSBP2 appeared to cooperate with homeobox B4 (HOXB4)-induced acute myeloid leukemia in a primate (Zhang et al., 2008) ; (ii) a reciprocal translocation resulting in an SSBP2-JAK2 fusion capable of functioning as a dominant negative SSBP2 allele was detected as the sole anomaly in an adult with acute preB lymphoblastic leukemia (Poitras et al., 2008) ; (iii) finally, SSBP2 is frequently silenced through epigenetic mechanisms in prostate cancer in contrast to benign prostatic hyperplasia (Liu et al., 2008) .
Mice hypomorphic for Ssbp3 resemble Lhx1 nulls with aberrant head structures and embryonic lethality showing SSBP3-LDB1-LHX1 interactions to be essential for normal development. Whether Ssbp2, with a 480% overall identity to Ssbp3 and 100% identity in the LDB1 interaction domain, is necessary for embryonic development is unknown. Thus, the roles of Ssbp2 in embryonic development and tumor suppression are important issues to resolve. Here, we report Ssbp2 to be dispensable for development. However, genetic ablation of Ssbp2 causes a broad range of oncogenic events, supporting its in vivo tumor suppressor activity.
Results
Ssbp2 null mice are viable and fertile but have a shortened lifespan The murine Ssbp2 gene, spanning 17 exons, is highly homologous to the human gene. To completely disrupt expression, a targeting vector was generated by replacing the first exon of Ssbp2 (encoding the initiation Met), with a neomycin resistance gene as detailed in 'Materials and methods'. The wild-type and targeted alleles were distinguished by single copy probes flanking the 5 0 and 3 0 ends of the targeted locus ( Figure 1a ). As shown in Figure 1b , Southern blotting experiments verified accurate targeting. Absence of Ssbp2 expression was further confirmed by immunoblotting. In heterozygous mice, SSBP2 levels were reduced to about 50%, whereas no protein was detected in null animals ( Figure 1c ).
Mice homozygous for the Ssbp2 mutation (Ssbp2
) were born at a lower frequency (B20%) than the predicted Mendelian ratio of 25% in the mixed S129/ SvEv Â C57/BL6 mixed background (Supplementary Table 1 ). This slight reduction in live births indicated a low penetrant lethality phenotype. Nonetheless, the general appearance of null mice was indistinguishable from that of wild type and heterozygous littermates. Total necropsies performed at 3 and 6 months of age were unremarkable. Additionally, there was no compensatory increase in Ssbp3 expression in the Ssbp2 À/À mice (Wang Y and Nagarajan L, unpublished results). Thus, despite extensive overlap in expression and 480% overall identity, targeted disruption of Ssbp2 yields an apparently different phenotype.
To investigate whether loss of Ssbp2 contributed to malignant transformation or other adult onset abnormalities, we monitored a cohort of Ssbp2 þ / þ (n ¼ 41), and Ssbp2 À/À (n ¼ 40) mice for a period of 2 years. KaplanMeier analysis showed a significant decrease in overall survival for null mice compared with wild-type littermates, with 50% of null mice dead by 68 weeks of age ( Figure 1d ).
Ssbp2 null mice exhibit enhanced predisposition to lymphomas and carcinomas
To identify the cause of this premature lethality, total necropsies were performed on 13 moribund mice (Supplementary Table 2a ). Histopathological analysis revealed disseminated lymphomas involving multiple organs in 6 of 13 mice (435, 486, 536, 572, 576 and 625) . There were carcinomas in 2 out of 13 mice, involving the Hardian gland (559) and lung (637), and one mouse (373) had an adenoma of the lung. Other significant findings were polyarteritis, glomerular nephropathy, anemia and degenerative joint disease. Additionally, total necropsies of 12 Ssbp2 À/À 'non-morbid' mice between 60 and 80 weeks of age (median age 68 weeks) revealed malignancies in six animals (Supplementary  Table 2b ). Four mice in this subset had microscopic lymphomas in multiple organs (414, 498, 538 and 617) , one had squamous cell carcinoma at hock in tibia (616) and the sixth mouse had an adenocarcinoma of jejunum and adenoma of the lung (575). Mouse 498 also had an unclassified sarcoma in the abdomen. Analogous to the moribund mice, chronic glomerular nephropathy and systemic polyarteritis were other significant findings in these mice. Thus, 62% of moribund and 50% of nonmoribund Ssbp2 À/À mice developed full-blown malignancies between 60 and 80 weeks of age. Frequently, the lymphomas were accompanied by lymphopenia and pancytopenia (Supplementary Table 3 ).
To determine whether Ssbp2 þ /À mice also show enhanced predisposition to malignancy we evaluated 11 age-matched mice by total necropsy. Of these, one mouse had a lymphoma and the second mouse had both a lymphoma and sarcoma. In contrast, no tumors were detected in age-matched, wild-type mice. The pie chart summarizes the tumor spectrum in Ssbp2 null and heterozygous mice (Figure 2) . Figure 3a shows a representative lymph node from mouse 538, in which malignant lymphoid follicles effaced the normal nodal architecture. At higher magnification, the lymphoma cells appeared intermediate to large in size and contained abundant eosinophilic cytoplasm (Figure 3b ). To better characterize the phenotype of the malignant lymphocytes, the tumors were examined for expression of the B-and T-cell markers B220 and CD3, respectively. Immunohistochemical staining detected strong B220 expression, supporting a B-cell phenotype (Figure 3c ). In contrast, this tumor was negative for CD3 (data not shown). The lymphomas had spread widely at the time of detection and had infiltrated parenchymal organs as shown in representative sections from the lung (mouse 576, Figure 3d ) and salivary gland (mouse 617, Figure 3e ). These findings are consistent with a high-grade large B-cell lymphoma. Carcinomas constituted the second most common malignancy. Figure 3f is an example of an aggressive bronchioalveolar carcinoma from mouse 637.
As B-cell lymphomas were the most common malignancy, we investigated the status B-cell differentiation in Ssbp2 À/À null bone marrow. Of the four stages of B-cell differentiation evaluated (pro-B, pre-B, immature and mature) a significant expansion of the pre-B-cell compartment was detected in the marrows from 6-weekold Ssbp2 À/À mice ( Figure 4 ). The findings raise the possibility of a critical role for Ssbp2 in pre-B to immature B transition.
Ssbp2 deficiency accelerates aggressive thymic lymphomas in Trp53 null mice Although the Ssbp2 À/À mice were on tumor watch, we were uncertain of the tumorigenic phenotype.
SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability Y Wang et al Furthermore, the tumors from Ssbp2 À/À mice were frequently microscopic. To determine whether loss of Ssbp2 À/À would cooperate with a known tumor suppressor Trp53 À/À we derived double null mice. For these studies, we used Trp53 null mice in BALB/c Â C57/BL6 background mice, which are predisposed to mammary carcinomas rather than lymphomas (Koch et al., 2007) . We did not readily detect an exacerbation of carcinomas or B-cell lymphomas in this mixed background. Unexpectedly, there was a 2.4-fold increase in thymic lymphomas. Twenty of 31 (65%) double null mice developed thymic lymphomas in contrast to 8 of 30 (27%) Trp53 À/À mice. As shown in Figure 5a , the median survival of Ssbp2 À/À Trp53 À/À mice was shortened to 122 days from 182 days for the Trp53 À/À mice (P ¼ 0.0019). On necropsy, large thymic masses infiltrating into the thoracic cavity were seen, and histologic examination revealed high-grade tumors with abundant mitoses (Figure 5b ).
The striking exacerbation of large thymic lymphomas in the double null mice, together with the relative abundance of SSBP2 transcripts in the normal thymus (Castro et al., 2002) provided an excellent model for further characterization of tumors lacking SSBP2. T-cell maturation is orchestrated in a stepwise regulatory process, with two major checkpoints at the double À/À tumor 1320 is double positive, a stage at which LMO2 is not expressed. However, in mouse 1332 despite the high CD8 expression the LMO2 levels were not high in contrast to tumors in mice 1521 and 1386. These findings also raise the possibility of an overall increase in LMO2 expression in the double null thymi or an expansion of the LMO2 expressing pre-T population in the pre-malignant thymus. However, LMO2 levels in 4-weeks-old thymi from Ssbp2 À/À Trp53 À/À were not higher than those of single nulls or wild type (Wang Y and Nagarajan L, unpublished results). Thus, the target cell for transformation in the Ssbp2 À/À Trp53 À/À appears to be an LMO2 expressing immature thymocyte.
It is also possible that expression of CD4, a known transcriptional target of E2A-and LDB1-containing complexes, as well as other T-cell-specific differentiation markers, were specifically inhibited or delayed in Ssbp2 null mice. A subtle alteration in the T-cell differentiation program in either the DP stage or DN4-DP transition, resulting in a clone that would normally be eliminated, appears to be the target of transformation in the absence of Trp53. To determine whether Ssbp2 has a stagespecific role in T-cell maturation, we examined its expression in cells selected by cell surface phenotype. Although Ssbp2 expression is detectable throughout T-cell differentiation, there is a dramatic increase at the DP stage and a subsequent decrease at the SP stage ( Supplementary Figure 2) , suggesting a role for Ssbp2 in DP cell homeostasis or DN4-DP transition.
When examined for histological alterations, the Ssbp2 À/À thymi were normal with distinct cortical and medullary zones. Although their sizes were similar at 1 month, Ssbp2 À/À thymi were smaller at 3 and 6 months of age. This reduction in thymic size was reflected in a substantial decrease in cellularity at 3 and 6 months of age (Figure 5d ). However, the percentage of DP or CD4, SP cells estimated by fluorescence-activated cell sorter (FACS) analysis was not significantly different between the Ssbp2 À/À mice and wild-type littermates (data not shown). Thus, genetic ablation of Ssbp2 appears to accelerate thymic atrophy analogous to oncogenic models of stem cell leukemia hematopoietic transcription factor (SCL)/LMO1 double transgenics, SCL transgenic in an E2A and HEB heterozygous background, and E2A-HLF transgenic mice (Smith et al., 1999; O'Neil et al., 2004) . If the cooperation between Ssbp2 and Trp53 is mediated by a dominant Ssbp2 dependent mechanism, the thymocytes from Ssbp2 À/À and Ssbp2
Trp53 À/À mice should express this phenotype. If homozygous loss of Ssbp2 was necessary and sufficient to enhance LDB1 turnover under physiological conditions, it may be causally linked to the accelerated lymphomagenesis. As shown in Figure 6a , LDB1 protein levels were diminished by Table 2 ) were used to determine the frequencies. (b) Eleven age-matched Ssbp2 þ /À mice were killed for total necropsy. Three malignancies were found in two mice. Numbers inside each slice denote the percentage of specific tumor type.
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À/À thymocytes. Importantly, LDB1 expression was considerably reduced in double null thymocytes. In contrast, LDB1 levels in Trp53 À/À null thymocytes were 480% of that in wild-type cells. Figure 6b shows that the differences in LDB1 protein levels were not because of transcriptional downregulation of Ldb1, as its mRNA did not vary by 410% between the strains. To confirm that the decrease in LDB1 levels was due to enhanced turnover, when the thymocytes from wild-type and null mice were placed in short-term culture and protein synthesis inhibited with cycloheximide, LDB1 levels decreased rapidly in null thymocytes. The estimated half-life of LDB1 in null thymocytes was 2 h compared to 44 h in wild-type thymocytes (Figure 6c) . In contrast to LDB1, E47 protein abundance and half-life were unaltered in the Ssbp2 À/À thymocytes (Supplementary Figure 3) . These findings thus establish that SSBP2 is a direct regulator of LDB1 protein levels in vivo.
To determine whether the altered LDB1 stability affected transcriptional targets in vivo, we examined the surrogate T-cell receptor pre-Ta, a direct transcriptional target of SCL-, LMO2-and LDB1-containing complexes (Tremblay et al., 2003) . In fact, pre-Ta expression was significantly reduced in the DN3 and DN4 stages of Ssbp2 À/À thymocytes (Figure 6d ), analogous to E2A and HEB null mice, suggesting SSBP2 may be a limiting component of LMO2-, E2A-and HEB-containing complexes. In contrast, pre-Ta regulation in DP thymocytes appeared to be independent of SSBP2, reminiscent of E2A null DP thymocytes, which are characterized by decreased expression in DN stages and not in DP cells (Tremblay et al., 2003) . Impaired pre-T-cell receptor signaling in Trp53 À/À mice causes transformation, (Haks et al., 1999) . In aggregate, these results suggest that homozygous loss of Ssbp2 provides a window for rapid transformation in the absence of Trp53.
Discussion
We establish the tumor suppressor activity of SSBP2 in this report. The development of multiple malignancies, including both lymphomas and carcinomas, in the Ssbp2 À/À mice (Figures 2 and 3 ; Supplementary Table 2), shows the in vivo suppressor activity. Although B-cell lymphoma was the predominant malignancy observed, the development of carcinomas and sarcomas underscores how LMO/LHX-LDB1-SSBP interaction might have a fundamental role in inhibiting neoplastic transformation in multiple tissues.
Although the precise levels of LHX, LMO and LIMbinding proteins have been shown to be important for a number of developmental programs, accumulating evidence implicates the context-dependent function of altered stochiometry of these complexes during oncogenesis. Together with the established oncogenic activity of LMO1 and LMO2 in human T-cell lymphomas, LMO3 in neuroblastoma and LMO4 in breast cancer and carcinoma of the oral cavity, (Aoyama et al., 2005; Sum et al., 2005; Nam and Rabbitts, 2006) , overexpression of LHX2 in chronic myeloid leukemia blast crisis (Wu et al., 1996) our findings reveal another component of a pathway affected in multiple malignancies. Preferential retroviral integrations into the Ssbp3 locus were identified when Trp53 À/À mice were challenged with retroviruses (Uren et al., 2008 ). LDB1 À/À mice also developed carcinomas such as this low-grade adenocarcinoma of lung. The tumor is composed of bland glandular structures lined with cuboidal to low columnar cells that invade the pulmonary stroma. Bars denote the magnification.
SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability Y Wang et al and RNF12 are also cofactors for estrogen receptor a-regulated target genes. In contrast to LHX-mediated transcription, LDB1 inhibits estrogen receptor amediated activation of target genes. More importantly, elevated LDB1 expression correlated with estrogen receptor, progesterone receptor positivity and impaired differentiation in primary breast tumors (Johnsen et al., 2009) . Inactivation of SSBP2 and inactivation/activation of related members SSBP3 and 4 may be a common mechanism to perturb normal differentiation regulated by LMO-and HLH-containing complexes during oncogenesis.
Ssbp2, a suppressor of B-cell lymphogenesis
The data presented here reveal SSBP2 to be a critical tumor suppressor in B lymphoid neoplasms. Consistent with this notion, deletions of 5q13-14 have been reported in a distinct subset of human diffuse large B-cell lymphomas (DLBCL) lacking BCL6 rearrangements (Cerretini et al., 2006) . Moreover, global expression profiling to distinguish Burkitt lymphoma from DLBCL identified high SSBP2 expression in Burkitt lymphoma compared to DLBCL (Dave et al., 2004) . Thus, the predisposition of Ssbp2 À/À mice to B-cell lymphoma provides the first clues on the significance of this pathway in DLBCL. A regulatory function for the LDB1-interacting LIM domain protein LMO2 has not been established in pro-B-lymphocytes, although aberrant expression of LMO2 is a marker for human DLBCL (Natkunam et al., 2008) . Of note, the E boxbinding proteins E2A, LYL1 and HEB, all, potentially, members of LMO2-and LDB1-containing transcriptional complexes, are also critical regulators of B-cell differentiation. Mice with targeted disruption of LYL1, HEB and E2A showed impaired B-cell differentiation (reviewed in Murre, 2005; Capron et al., 2006) . Our preliminary analyses of bone marrow-derived B cells show a modest increase in pre-B cells from 6-weeks-old Ssbp2 À/À mice (Figure 4) recapitulating some of the alterations seen in the b-HLH null mice. Further studies in purified strains will determine how the subtle alteration in B-cell program contributes to lymphomagenesis.
Loss of Ssbp2 cooperates with Trp53 deletion through decreased LDB1 stability Thymic lymphomas are significantly exacerbated in the absence of Trp53 (Figure 5, Supplementary Figure 1) . Abundant LMO2 expression in these tumors suggests these cells to be immature thymocytes (DN). Interestingly, LMO2 and LHX2 levels are stabilized in an LDB1-dependent manner in erythroid and pituitary cells (Gungor et al., 2007; Xu et al., 2007; Cai et al., 2008) . The present findings of high LMO2 in the context of rapidly turning over LDB1 raises a possible SCL/HEBmediated stabilization during specific stages of differentiation (Lecuyer et al., 2007) . Our findings implicate compromised checkpoint responses in the absence of Ssbp2 and Trp53 to underlie the accelerated transformation seen in these cells. Such a model is supported by impaired differentiation in mice with aberrant T-cell receptor b rearrangement because of inactivation of the cis element Eb (Eb
). Loss of Trp53 in these mice induces CD8
þ T-cell lymphomas (Haines et al., 2006) . In conclusion, Ssbp2 is a potent in vivo tumor suppressor and modulator of LDB1 activity. Although this gene was isolated as a candidate acute myeloid leukemia suppressor, the Ssbp2 null mice did not develop overt myeloid leukemia. Likewise, we did not find prostate malignancies in the null mice although the human ortholog is silenced by methylation. Ssbp2 expression is very high, in hematopoietic stem and progenitor cells, a common target for myeloid transformation (Li J, Wang Y and Nagarajan L, unpublished results). Indeed, global expression profiling reveals decreased SSBP2 transcripts in SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability Y Wang et al primary acute myelogenous leukemia initiating cells in contrast to normal hematopoietic stem cells (Majeti et al., 2009) . As thymic lymphomas became evident only in the context of Trp53 loss, lack of myeloid or prostatic malignancies might reflect the absence of cooperating mutations. Future studies will establish the myeloid leukemogenic potential Ssbp2 null bone marrow and the relevant leukemogenic mutations.
Materials and methods
Targeted disruption of murine Ssbp2 gene A mouse Ssbp2 cDNA clone was used to screen a lambda phage mouse genomic library to obtain part of the gene. A targeting vector was designed to replace exon 1 with PGK-Neo flanked by 3.1 kbp 5 0 and 3.7 kbp 3 0 genomic sequences from the Ssbp2 locus and thymidine kinase for double selection. Targeted recombinants were verified by Southern blot analysis with unique 5 0 and 3 0 probes outside the targeted locus ( Figure 1a) . Mouse embryonic stem cells (129/SvEv) transfected with the targeting vector underwent double selection before microinjection into C57/BL6 blastocysts. Chimeric offsprings were crossed with C57/BL6 mice and germ line transmission verified. Ssbp2 À/À mice were crossed to Trp53 À/À mice in a BALB6 Â C57/BL6 mixed background, a gift from Koch and Lozano (Koch et al., 2007) , to generate Ssbp2
Trp53 þ /À mice, which were then bred to generate double null mice. Genotyping for Trp53 was performed by polymerase chain reaction (PCR) as described earlier (Jacks et al., 1994) . All mice were maintained in a conventional-specific-pathogenfree facility according to the NIH guidelines using an approved Western blotting Immunoblots were developed with rabbit polyclonal antibodies to SSBP2 (1:10,000) as detailed earlier (Liang et al., 2005) . Goat antibody to LDB1 (1:250), goat antibody to LMO2 (1:250) and goat antibody to E2A (1:250) were used under the same conditions. The mouse monoclonal antibody against human histone H1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as loading control. À/À thymocytes. Ssbp2 transcripts in 4-weeks-old thymi were estimated by real-time PCR. Results show that Ldb1 transcript levels were similar between all the four genotypes tested. Data represent average of two separate experiments each with triplicate reactions. (c) LDB1 half-life is shortened in the absence of Ssbp2. Short-term cultured thymocytes from wild type and Ssbp2 À/À mice were treated with cycloheximide for the indicated lengths of time and nuclear extracts isolated were examined for LDB1 levels by immunoblotting. Protein loading was quantified by Ponceau staining. The signals were analyzed by IMAGE analysis software and the ratios at various time points plotted to determine LDB1 halflife. (d) Pre-Ta expression is decreased in Ssbp2 À/À thymus. Thymocytes from 4-weeks-old mice were divided into seven subsets. Realtime PCRs were performed on purified cell populations using specific primers for pTa. For each cDNA pool, transcript levels were normalized against 18S RNA within that sample. Two separate experiments, each with triplicate reactions, were done.
SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability Y Wang et al Short-term culture of T-lymphocytes Thymi were collected from 6-week-old mice and placed in 3 ml of tissue culture medium. Short-term culture conditions were identical to those described by Baseta and Stutman (2000) . Single-cell suspensions were prepared by passage through an 18G needle and cell strainer (BD Falcon #352350). Cells were cultured for an hour in a 100 mm dish at a density of 2.2 Â 10 6 / ml before treatment with cycloheximide, collected, washed with PBS. 10 mg of nuclear extracts were resolved in 10% NuPAGE gels (Invitrogen) and transferred to PVDF membranes for immunoblotting.
Reverse transcriptase coupled RT-PCR Total RNA was prepared by Qiagen's RNeasy Micro kit (No.74004, Qiagen, Valencia, CA, USA) or Mini kit according to manufacturer's instructions. For first-strand cDNA synthesis, 1 mg of total RNA, 20 pmol Oligo(dT) 12-18 and 200 units SuperScript II Reverse transcriptase (Invitrogen) were mixed in a final volume of 20 ml. In all, 1 ml cDNA, thus, generated was added to the 20 ml PCR mixture containing 1 Â TaqMan Gene Expression Assay primers (Applied Biosystems, Foster City, CA, USA) and 1 Â TaqMan Universal PCR Master Mix (4324018, Applied Biosystems). Each sample was amplified in triplicate. The PCR consisted of 40 cycles of denaturation at 95 1C for 15 s, annealing and amplification at 60 1C for 60 s in an ABI7900HT Sequence Detection System Machine (Applied Biosystems). The specific number for TaqMan Gene Expression Assay primers are Ssbp2: Mm00452502_m1; Ldb1: Mm00440147_m1; pTa: Mm00478363_m1; Lmo2: Mm00493153_m1; 18S rRNA primers (4319413E) were used as internal control. The specific position and length of all these PCR products can be found on Applied Biosystems website.
